Global Peptide-Based Vaccines for Cancer Market Growth 2025-2031
Description
The global Peptide-Based Vaccines for Cancer market size is predicted to grow from US$ 68.4 million in 2025 to US$ 112 million in 2031; it is expected to grow at a CAGR of 8.6% from 2025 to 2031.
Peptide-Based Vaccines for Cancer, is an anti-tumor therapeutic vaccine with the most researches, the best effect and the most mature technology among various therapeutic vaccines. Known as subunit vaccines, compared with traditional inactivated and attenuated vaccines, peptide vaccines can not only be used as preventive vaccines against infectious or non-infectious diseases, but also for the treatment of Alzheimer's disease, malignant tumors, etc.; peptide vaccines have become a new strategy for anti-tumor at present, and peptide anti-tumor therapeutic vaccines have accounted for the largest proportion of biotechnology anti-cancer new drugs under development.
United States market for Peptide-Based Vaccines for Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Peptide-Based Vaccines for Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Peptide-Based Vaccines for Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Peptide-Based Vaccines for Cancer players cover AmbioPharm, Almac, ACT, Ultimovacs, Marker Therapeutics, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Peptide-Based Vaccines for Cancer Industry Forecast” looks at past sales and reviews total world Peptide-Based Vaccines for Cancer sales in 2024, providing a comprehensive analysis by region and market sector of projected Peptide-Based Vaccines for Cancer sales for 2025 through 2031. With Peptide-Based Vaccines for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide-Based Vaccines for Cancer industry.
This Insight Report provides a comprehensive analysis of the global Peptide-Based Vaccines for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide-Based Vaccines for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide-Based Vaccines for Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide-Based Vaccines for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide-Based Vaccines for Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide-Based Vaccines for Cancer market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Synthetic Polypeptide Vaccines
Recombinant Polypeptide Vaccine
Other
Segmentation by Application:
Infectious Disease Prevention
Cancer Immunotherapy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AmbioPharm
Almac
ACT
Ultimovacs
Marker Therapeutics, Inc.
Immatics
OncoPep
Anergis
Sellas Life Sciences
Immatics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Peptide-Based Vaccines for Cancer market?
What factors are driving Peptide-Based Vaccines for Cancer market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Peptide-Based Vaccines for Cancer market opportunities vary by end market size?
How does Peptide-Based Vaccines for Cancer break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Peptide-Based Vaccines for Cancer, is an anti-tumor therapeutic vaccine with the most researches, the best effect and the most mature technology among various therapeutic vaccines. Known as subunit vaccines, compared with traditional inactivated and attenuated vaccines, peptide vaccines can not only be used as preventive vaccines against infectious or non-infectious diseases, but also for the treatment of Alzheimer's disease, malignant tumors, etc.; peptide vaccines have become a new strategy for anti-tumor at present, and peptide anti-tumor therapeutic vaccines have accounted for the largest proportion of biotechnology anti-cancer new drugs under development.
United States market for Peptide-Based Vaccines for Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Peptide-Based Vaccines for Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Peptide-Based Vaccines for Cancer is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Peptide-Based Vaccines for Cancer players cover AmbioPharm, Almac, ACT, Ultimovacs, Marker Therapeutics, Inc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LP Information, Inc. (LPI) ' newest research report, the “Peptide-Based Vaccines for Cancer Industry Forecast” looks at past sales and reviews total world Peptide-Based Vaccines for Cancer sales in 2024, providing a comprehensive analysis by region and market sector of projected Peptide-Based Vaccines for Cancer sales for 2025 through 2031. With Peptide-Based Vaccines for Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Peptide-Based Vaccines for Cancer industry.
This Insight Report provides a comprehensive analysis of the global Peptide-Based Vaccines for Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Peptide-Based Vaccines for Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Peptide-Based Vaccines for Cancer market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Peptide-Based Vaccines for Cancer and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Peptide-Based Vaccines for Cancer.
This report presents a comprehensive overview, market shares, and growth opportunities of Peptide-Based Vaccines for Cancer market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Synthetic Polypeptide Vaccines
Recombinant Polypeptide Vaccine
Other
Segmentation by Application:
Infectious Disease Prevention
Cancer Immunotherapy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
AmbioPharm
Almac
ACT
Ultimovacs
Marker Therapeutics, Inc.
Immatics
OncoPep
Anergis
Sellas Life Sciences
Immatics
Key Questions Addressed in this Report
What is the 10-year outlook for the global Peptide-Based Vaccines for Cancer market?
What factors are driving Peptide-Based Vaccines for Cancer market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Peptide-Based Vaccines for Cancer market opportunities vary by end market size?
How does Peptide-Based Vaccines for Cancer break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
90 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Peptide-Based Vaccines for Cancer by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Peptide-Based Vaccines for Cancer by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
